

AMENDMENTS

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently Amended) A sustained release pharmaceutical dosage form, ~~which is held in a buccal or sublingual location, comprising a pharmaceutically or nutritionally active agent that is not absorbed through the oral mucosa to a substantial extent and that exhibits an absorption window of less than 6 hours in the gastrointestinal tract, in a sustained release matrix formulation, whereby the active agent is released gradually over an extended time period and swallowed to be absorbed systemically in the gastrointestinal tract~~ consisting of (i) a sustained release matrix selected from a fat-wax matrix and a polymeric matrix, which matrix comprises a mixture of a pharmaceutically active agent and a polymeric material selected from a hydrophilic polymer and inert plastic; and (ii) a retaining means for securing the dosage form in a buccal or sublingual location.

2. (Canceled).

3. (Original) The dosage form of claim 1, which is a layered tablet.

4. (Currently Amended) The dosage form of claim 1, wherein ~~one surface of the dosage form contains~~ the retaining means is a mucoadhesive, ~~which will function to hold the dosage form in place in the buccal or sublingual location.~~

5. (Currently Amended) The dosage form of claim 1, wherein the ~~matrix formulation is held in the buccal or sublingual location by~~ the retaining means is a holding device.

6. (Canceled).

7. (Original) The dosage form of claim 1, wherein the active agent is doxycycline, trospium chloride, clonazepam, ampicillin, amoxicillin, riboflavin, levadopa, talinolol, furosemide, cefixime or cyclosporin.

8-13. (Canceled).

14. (Currently Amended) A process for preparing the dosage form of claim 1, comprising combining ~~[[a]]~~ the pharmaceutically ~~or nutritionally~~ active agent with matrix materials and fabricating into a tablet or disc.

15. (Original) The process of claim 14, further comprising applying a mucoadhesive to one surface of the tablet or disc.

16. (New) The dosage form of claim 1, wherein the pharmaceutically or nutritionally active agent is one that is not absorbed through the oral mucosa to a substantial extent .

17. (New) The dosage form of claim 1, wherein the hydrophilic polymer is selected from sodium carboxymethylcellulose, methylcellulose, hydroxypropylcellulose, hydroxyethyl cellulose, polyethylene oxide, polyvinyl pyrrolidone, polyvinyl acetate, carboxyl polymethylene, alginic acid, gelatin, and natural gum.

18. (New) The dosage form of claim 1, wherein the inert plastic material is selected from polyvinyl chloride, polyethylene, vinyl acetate/vinyl chloride copolymer, vinylidene chloride/acrylonitrile copolymer, acrylate methylmethacrylate copolymer, ethyl cellulose, cellulose acetate, and polystyrene.